NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
The present Phase 2 clinical study will evaluate the safety and immunogenicity of the immunogenic formulation cGMP rBCG-N-RSV of 100,000 CFU in adults over 60 years of age.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.